1401 completed, 359 unknown, 332 recruiting, 317 terminated. 1641 Phase 2, 751 Phase 1, 680 Phase 3, 60 Not applicable, 30 Phase 4.
Follow Paclitaxel: new trials by email Literature Review of Paclitaxel trials Research Report on Paclitaxel
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry. Gemcitabine (1000 mg/m^2), Paclitaxel 80 mg/m2 weekly - Triple Negative Breast Cancer, Metastatic Triple-negative Breast Cancer | Phase 2 | Not yet recruiting | The University of The West Indies | 750 | 2027-06-01 | 2026-09-22 |
| Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer AST-201, Paclitaxel, Carboplatin - Advanced Ovarian Cancer | Phase 2 | Not yet recruiting | Aston Sci. Inc. | 98 | 2027-06-01 | 2026-10-27 |
| A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck Cemiplimab, Fianlimab, Carboplatin - Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | University of Chicago | 90 | 2027-02-07 | 2026-01-20 |
| Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer losartan, Paclitaxel - Platinum Resistant Ovarian Cancer | Phase 2 | Not yet recruiting | Massachusetts General Hospital | 27 | 2027-02-01 | 2026-09-22 |
| Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer Cemiplimab, Pemetrexed (1), Cisplatin - Non-Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Medical University of South Carolina | 38 | 2027-02-01 | 2026-11-10 |
| Delayed Application of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Cisplatin, Carboplatin, Pemetrexed - Advanced NSCLC, Metastatic NSCLC - Non-Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Goethe University | 198 | 2027-02-01 | 2026-11-17 |
| US/PA/E Imaging for Early Identification of Tumor Response in Patients With Stage II-III Triple Negative Breast Cancer Receiving Neoadjuvant Immunotherapy and Chemotherapy Elastography, Magnetic Resonance Imaging, Photoacoustic Imaging - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 | Phase 2 | Not yet recruiting | Emory University | 32 | 2027-01-01 | 2026-11-04 |
| Immune Checkpoint Blockade and Chemotherapy With or Without Fecal Microbiota Transplant in Advanced Non-Small Cell Lung Cancer LND101, Carboplatin, Pemetrexed - Non Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Canadian Cancer Trials Group | 160 | 2026-12-31 | 2026-10-27 |
| Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma Tislelizumab - Esophageal Cancer | Phase 3 | Not yet recruiting | Asan Medical Center | 172 | 2026-12-31 | 2026-10-29 |
| Aspirin and PAClitaxel in Head & Neck Squamous Cell Carcinoma Aspirin, Paclitaxel - Head and Neck (HNSCC), Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | Phase 2 | Not yet recruiting | Washington University School of Medicine | 40 | 2026-12-31 | 2026-10-28 |
| Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) Carboplatin, Paclitaxel, Nab-paclitaxel - Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Recruiting | Exelixis | 60 | 2026-12-15 | 2026-11-12 |
| Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients Paclitaxel, Carboplatin, Pembrolizumab - Triple Negative Breast Cancer | Phase 1 | Not yet recruiting | Washington University School of Medicine | 30 | 2026-12-01 | 2026-11-05 |
| A Study of QLS5132 in Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer QLS5132, Liposomal Doxorubicin, Paclitaxel - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 420 | 2026-12-01 | 2026-11-09 |
| A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220) Pumitamig, Carboplatin, Cisplatin - Early-Stage Non-Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Bristol-Myers Squibb | 80 | 2026-11-30 | 2026-10-13 |
| Dexamethasone De-Escalation in Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast Cancer Dexamethasone, Famotidine, Diphenhydramine - Triple Negative Breast Cancer, Triple Negative Breast Cancer (TNBC) | Phase 2 | Not yet recruiting | Washington University School of Medicine | 17 | 2026-11-30 | 2026-11-03 |
| Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) azacytidine, carboplatin, paclitaxel - Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 60 | 2026-11-24 | 2026-11-19 |
| Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial Cancer Dostarlimab, Carboplatin and paclitaxel - Endometrial Carcinoma, Neoplasms, Endometrial | Phase 3 | Not yet recruiting | GlaxoSmithKline | 378 | 2026-11-12 | 2026-10-19 |
| Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Biospecimen Collection, Computed Tomography, Futibatinib - Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Phase 1 | Recruiting | Northwestern University | 18 | 2026-11-10 | 2026-11-19 |
| Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung Cancer Lurbinectedin, Paclitaxel - Carcinoma, Small Cell Lung | Phase 2 | Not yet recruiting | Yonsei University | 69 | 2026-11-01 | 2026-09-04 |
| Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets Ivonescimab, Carboplatin, Pemetrexed - Non Small Cell Lung Cancer | Phase 2 | Not yet recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 158 | 2026-11-01 | 2026-06-04 |
Showing 20 of 2873. Sign in to see all of them.
Breast Neoplasms (583) · Carcinoma, Non-Small-Cell Lung (503) · Ovarian Neoplasms (335) · Lung Neoplasms (211) · Fallopian Tube Neoplasms (157) · Neoplasms (152) · Stomach Neoplasms (130) · Triple Negative Breast Neoplasms (130) · Esophageal Neoplasms (128) · Neoplasm Metastasis (124) · Carcinoma, Ovarian Epithelial (116) · Endometrial Neoplasms (99) · Squamous Cell Carcinoma of Head and Neck (99) · Uterine Cervical Neoplasms (81) · Esophageal Squamous Cell Carcinoma (80)
National Cancer Institute (NCI) (159) · M.D. Anderson Cancer Center (72) · Merck Sharp & Dohme LLC (72) · Hoffmann-La Roche (64) · AstraZeneca (47) · Bristol-Myers Squibb (45) · Memorial Sloan Kettering Cancer Center (44) · Eli Lilly and Company (38) · Gynecologic Oncology Group (37) · Alliance for Clinical Trials in Oncology (32) · Fudan University (29) · Genentech, Inc. (28) · Novartis Pharmaceuticals (28) · Eastern Cooperative Oncology Group (26) · SWOG Cancer Research Network (26)
United States (1569) · China (562) · Spain (367) · France (328) · South Korea (323) · Canada (302) · Italy (301) · Germany (292) · United Kingdom (262) · Japan (216) · Belgium (211) · Australia (209) · Taiwan (192) · Poland (189) · Brazil (153)
Norman Wolmark, MD (9) · Corey J. Langer, MD (8) · Francesco Perrone, M.D., Ph.D. (8) · Mariano Provencio, MD (8)
PMID 37185961, PMID 34037241, PMID 32450725, PMID 35170751, PMID 38431043, PMID 40966692, PMID 21502559, PMID 21941283, PMID 22646630, PMID 25092775, PMID 30633128, PMID 31395089, PMID 35101941, PMID 37465924, PMID 16236738, PMID 16394300, PMID 18398152, PMID 19692680, PMID 22204724, PMID 22204725, PMID 22508812, PMID 22547591, PMID 23860537, PMID 24077916, PMID 24637997, PMID 24662947, PMID 24794243, PMID 25057165, PMID 25332249, PMID 25366678, PMID 25403584, PMID 26056183, PMID 26101239, PMID 26313683, PMID 26454620, PMID 28196905, PMID 28434660, PMID 29501363, PMID 29562804, PMID 30207593, PMID 30808774, PMID 30976202, PMID 31622131, PMID 32101663, PMID 32305010, PMID 32599071, PMID 33084020, PMID 33154826, PMID 33231285, PMID 33538338
2023 (55), U10CA180868 (53), U10CA027469 (36), 2014 (30), 2016 (29), 2018 (29), U10CA031946 (26), U10CA032102 (25), 2017 (22), 2015 (20), 2025 (19), 2009 (18), 2019 (17), U10CA180820 (16), U10CA021115 (14)